Connect Biopharma Holdings Ltd Total Liabilities
Connect Biopharma Holdings Ltd total liabilities. Based on the latest financial reports, Connect Biopharma Holdings Ltd (CNTB) has total liabilities worth $16.61 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CNTB asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Connect Biopharma Holdings Ltd (2018–2025)
Total liabilities of Connect Biopharma Holdings Ltd from 2018 to 2025. This chart illustrates how Connect Biopharma Holdings Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore CNTB strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Connect Biopharma Holdings Ltd Competitors by Total Liabilities
The table below lists competitors of Connect Biopharma Holdings Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tritax Big Box REIT plc
LSE:BBOX
|
UK | GBX2.82 Billion |
|
Kalaris Therapeutics, Inc.
NASDAQ:KLRS
|
USA | $41.25 Million |
|
Promateris SA
RO:PPL
|
Romania | RON118.86 Million |
|
Sinil Pharmaceutical Co. Ltd
KQ:012790
|
Korea | ₩18.23 Billion |
|
Sietel Ltd
AU:SSL
|
Australia | AU$9.16 Million |
|
Abrdn PLC
LSE:ABDN
|
UK | GBX6.47 Billion |
|
Riverview Rubber Estates Bhd
KLSE:2542
|
Malaysia | RM33.39 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Connect Biopharma Holdings Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Connect Biopharma Holdings Ltd assets under control.
Liquidity & Leverage Metrics
Connect Biopharma Holdings Ltd Total Liabilities Ratios Explained
Connect Biopharma Holdings Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Connect Biopharma Holdings Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Connect Biopharma Holdings Ltd (2018–2025)
The table below shows the annual total liabilities of Connect Biopharma Holdings Ltd from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $14.10 Million | +54.58% |
| 2024-12-31 | $9.12 Million | -64.77% |
| 2023-12-31 | $25.88 Million | +56.64% |
| 2022-12-31 | $16.52 Million | -12.10% |
| 2021-12-31 | $18.80 Million | -62.01% |
| 2020-12-31 | $49.47 Million | +255.63% |
| 2019-12-31 | $13.91 Million | -84.32% |
| 2018-12-31 | $88.70 Million | -- |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.